TRT, GLP-1, and Peptide Access by Country: Regional Guides Directory

Regulatory status, customs enforcement, and clinic offerings change. Each guide describes the market as of its publication date in 2026. None of this is medical or legal advice. Consult a licensed provider in your country before starting any protocol.

We've spent the last year working with users in non-US markets who told us the same thing: the global GLP-1 and peptide conversation defaults to American assumptions about FDA approval, insurance, and compounding pharmacies, and most of that just doesn't apply if you live anywhere else. So we wrote real guides for real markets. Pricing in local currency, the actual prescribing pathway, whether national health systems cover anything, and what private routes look like.

Pick your country below. If your market isn't here yet, we're working through the list and the most-requested ones get prioritized. Email us if there's somewhere specific you'd like covered.

Europe

United Kingdom

UK access is mature for GLP-1 (NHS + private) and improving for TRT. Mounjaro and Wegovy are available privately through online clinics with pricing in the GBP 150-300/month range. Research peptides sit in a legal grey area but are commonly accessed through compounding-style routes. See the UK Wegovy and Mounjaro NHS guide and the UK peptides access guide.

Ireland

TRT is prescribed through endocrinologists with relatively conservative dosing. Read the Ireland TRT guide.

Italy

Italy has a structured private clinic network for both TRT and GLP-1, with the public SSN covering hormonal therapy under specific criteria. Pricing tends to be lower than UK or Germany private. Guides: TRT in Italy, GLP-1 in Italy, peptides in Italy.

Denmark

Nordic markets have strong public healthcare coverage for diabetes-indication GLP-1 but limited routes for off-label use. Private TRT exists but is uncommon. TRT in Denmark, GLP-1 in Denmark, peptides in Denmark.

Finland

Kela coverage details for Ozempic plus an emerging private TRT scene. TRT in Finland, GLP-1 in Finland, peptides in Finland.

Norway

TRT in Norway, GLP-1 in Norway, peptides in Norway.

Sweden

TRT in Sweden, GLP-1 in Sweden, peptides in Sweden.

Hungary

Strong private clinic scene in Budapest with English-speaking endocrinologists. GLP-1 in Hungary.

Serbia

GLP-1 in Serbia.

North America

Canada

Canadian access is well-developed: Health Canada has approved most major GLP-1 medications, provincial coverage varies, and naturopathic doctors offer a route for peptides that doesn't exist in the US. TRT in Canada, GLP-1 in Canada, peptides in Canada, compounded GLP-1 in Canada.

Mexico

Mexico is the most-used cross-border source for US patients seeking lower-cost access. Pharmacy purchase rules vary by state. TRT in Mexico, GLP-1 in Mexico, peptides in Mexico.

Asia-Pacific

India

India has rapidly become a major GLP-1 market with both branded imports and domestic generics in development. TRT in India, GLP-1 in India.

Korea

Seoul's anti-aging clinic infrastructure (Gangnam, Apgujeong, Cheongdam) supports an active peptide market through medical channels. Peptides in Korea.

Philippines

Manila private clinics handle most TRT and GLP-1 access. Filipino-language guide also available. TRT in the Philippines, GLP-1 in the Philippines, peptides in the Philippines, GLP-1 sa Pilipinas (Filipino).

Malaysia

TRT in Malaysia, GLP-1 in Malaysia.

Latin America

Argentina

Strong endocrinology tradition with both public (obras sociales) and private pathways. TRT in Argentina, GLP-1 in Argentina.

Africa and Middle East

United Arab Emirates

Strong private clinic network in Dubai and Abu Dhabi with branded Ozempic, Wegovy, and Mounjaro through licensed pharmacies. Insurance covers T2D indications but rarely weight management. GLP-1 in the UAE.

South Africa

Medical scheme coverage varies; private GP routes are well-established. TRT in South Africa, GLP-1 in South Africa, peptides in South Africa.

Cross-Market Reference

For a side-by-side comparison of the six largest GLP-1 markets (US, UK, Canada, Australia, EU, Mexico) including pricing, insurance coverage, and compounded options, see the GLP-1 access by country guide. For the cost breakdown of TRT internationally, see the TRT cost guide.

How These Guides Are Written

Each guide is researched against the regulator's official list (MHRA, EMA, Health Canada, MFDS, ANMAT, etc.), current pricing from named private clinics, and where possible cross-checked with users in that country. We update them when major regulatory shifts happen, like the FDA semaglutide-shortage decision or NHS Wegovy rollout changes. If you find something out of date, email us and we'll prioritize the update.